Shire Pharmaceutical Group's decision to buy the loss-making US biotech Transkaryotic Therapies (TKT) for US$1.57 B has split the opinion of analysts and investors alike. Although there are a number of positives to be gained from such a move, various criticisms have been voiced, particularly at the size of the purchase price. What is more, it remains to be seen whether the acquisition will actually materialise.